Introduction
cancers
SOFT TISSUE SARCOMA, CANCERS, NEOPLASMS, STS
Soft tissue sarcomas (STSs) are a heterogeneous group of more than 50 distinct mesenchymal neoplasms together composing 1% of all cancers. Despite incremental advances, median overall survival for patients with metastatic STS remains approximately 24 months.As a key exploratory end point, we characterized changes in the T-cell receptor (TCR) repertoire following GLA-SE. Metrics evaluating TCR clonality and diversity in tumor-infiltrating lymphocytes (TILs) have been associated with patient outcome in a number of settings.